| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,030 | 1,090 | 13:30 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09.25 | Fluicell AB receives observation status | 272 | GlobeNewswire | On August 29, 2025, Fluicell AB (the "Company") published its half-year report for 2025 with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market... ► Artikel lesen | |
| 26.03.25 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 26.03.2025 | 412 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.03.2025
Aktien
1 CA25383T1003 Digital Commodities... ► Artikel lesen | |
| 25.03.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | 668 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| 25.03.25 | XFRA ISIN CHANGE | 775 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA05553A1075 The BC Bud Corp. 25.03.2025 CA25383T1003 The BC Bud Corp. 26.03.2025 Tausch 1:1SE0010831321 Fluicell... ► Artikel lesen | |
| FLUICELL Aktie jetzt für 0€ handeln | |||||
| 25.03.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2025 | 489 | Xetra Newsboard | Das Instrument 6T8 KYG365731069 FOS.TOUR.GRP EO-,0001 EQUITY wird cum Kapitalmassnahme gehandelt am 25.03.2025 und ex Kapitalmassnahme am 26.03.2025 The instrument 6T8 KYG365731069 FOS.TOUR.GRP EO-... ► Artikel lesen | |
| 21.03.25 | Reverse Split and Change of ISIN for Fluicell AB | 381 | GlobeNewswire | Referring to the press release from Fluicell AB on March 20, 2025, the company will carry out a reverse stock split in relations 1:350. The share will be traded under new ISIN code with effect from... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,370 | -7,77 % | Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva - von First Berlin Equity Research GmbH
25.02.2026 / 17:11 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt... ► Artikel lesen | |
| AMGEN | 330,70 | +0,24 % | AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer | ||
| EPIGENOMICS | 1,020 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| STRYKER | 330,20 | -0,27 % | $100 Invested In Stryker 15 Years Ago Would Be Worth This Much Today | ||
| HEIDELBERG PHARMA | 2,830 | -5,35 % | HEIDELBERG PHARMA AG unter Beobachtung | ||
| OCUGEN | 1,617 | -2,36 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| BIO-GATE | 0,630 | -4,55 % | BIO-GATE AG: Stabilität mit mittelfristigem Fokus | ||
| SAREPTA THERAPEUTICS | 13,550 | -2,90 % | Sarepta Therapeutics, Inc. - 10-K, Annual Report | ||
| CARDIOL THERAPEUTICS | 0,860 | -0,81 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| 10X GENOMICS | 19,350 | -2,25 % | Breaking Down 10x Genomics: 11 Analysts Share Their Views | ||
| CSTONE PHARMACEUTICALS | 0,720 | -0,69 % | CStone Pharmaceuticals: CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate... ► Artikel lesen | |
| USANA HEALTH SCIENCES | 17,000 | +0,59 % | USANA Chairman & CEO Kevin Guest Urges Leaders to Use Reading as a Competitive Advantage in National Reading Month | ||
| BIO-TECHNE | 48,400 | -2,42 % | Bio-Techne's Ella Immunoassay Platform Receives CE-IVD Marking In EU | WASHINGTON (dpa-AFX) - Bio-Techne Corp. (TECH) said its Ella benchtop immunoassay platform has received CE-IVD marking and is now available for clinical use across the European Union. The CE-IVD... ► Artikel lesen | |
| INNATE PHARMA | 1,388 | -3,48 % | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| VERACYTE | 30,200 | -2,58 % | Cathie Wood's ARK sells Veracyte stock, buys MercadoLibre |